LeoGard 11.25 mg (Leuprorelin Acetate Injection) contains Leuprorelin Acetate, a synthetic gonadotropin-releasing hormone (GnRH) agonist designed for long-acting hormonal therapy for cancer. It is widely prescribed in oncology and gynecology for managing hormone-sensitive conditions by suppressing testosterone and estrogen production.

🔬 How LeoGard 11.25 mg Works

Leuprorelin initially stimulates and then suppresses the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), resulting in decreased testosterone in men and estrogen in women. This hormonal suppression helps slow the progression of hormone-dependent diseases.

💊 Indications

LeoGard 11.25 mg is commonly used for:

• Advanced Prostate Cancer
• Endometriosis Management
• Uterine Fibroids (Leiomyoma)
• Central Precocious Puberty (CPP)
• Hormone-responsive breast cancer (as directed by oncologists)

📌 Key Features of LeoGard 11.25 mg

• Strength: 11.25 mg
• Dosage Form: Long-acting depot injection
• Duration: Typically administered once every 3 months (as prescribed)
• Mechanism: GnRH agonist for hormone suppression
• Therapeutic Category: Hormonal therapy / Oncology & Gynecology treatment

⚕️ Administration & Monitoring

• Administered via intramuscular or subcutaneous injection by a healthcare professional.
• Regular monitoring of hormone levels and disease progression is recommended.
• Temporary hormone flare may occur during initial treatment phase.

⚠️ Precautions

• Possible side effects include hot flashes, mood changes, bone density reduction, and injection-site reactions.
• Long-term use may require bone health monitoring.
• Use under strict medical supervision only.

LeoGard 11.25 mg (Leuprorelin Acetate Injection) is an effective long-acting hormonal therapy option that helps manage hormone-dependent cancers and gynecological disorders, improving patient outcomes with controlled and sustained hormone suppression.